SOLVSOLVHealthcare · Medical Instruments & Supplies

SOLV Stock Forecast: Solventum Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$85
−1.50% on the day

The 15 Wall Street analysts covering Solventum Corp. hold a median 12-month price target of $100 — +18.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 76 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$14.4B
Ticker Nerd rank
76/ 100
Median analyst target
$100
Analysts covering
15
Revenue$2.2B+2.2% y/y
Operating income$181.0M
Net income$93.0M
Free cash flow$144.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.1%
1M
−2.2%
YTD
+6.7%
1Y
+6.3%
From 52W high
−8.6%
From 52W low
+35.2%
$62
$92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Solventum Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
76/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
89
Revisions
86
Momentum
81
Volatility
76
Issuance
65
Quality
54
Accruals
51
Growth
34

Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (34): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SOLV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SOLV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100$110$120Jan 26Apr 26Jul 26Oct 26SOLVHigh $115Median $100Low $75

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
8
Buy
5
Hold
2
Sell
$75
Low
$100
Median
$115
High

The green dot is the last close — the median target sits +18.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Nov 2026Piper SandlerReiteratesOverweight$105 → $110
6 Nov 2026Wells FargoMaintainsEqual-Weight$89 → $95
14 Sept 2026BTIGReiteratesBuy$95
6 Aug 2026BTIGMaintainsBuy$91 → $95
6 Aug 2026KeybancMaintainsOverweight$93 → $102
6 Aug 2026Piper SandlerMaintainsOverweight$92 → $105
6 Aug 2026StifelMaintainsBuy$90 → $100
6 Aug 2026UBSMaintainsBuy$95 → $101
6 Aug 2026WedbushMaintainsOutperform$94 → $101
28 July 2026UBSUpgradeBuy$95
9 July 2026BMO CapitalInitiatesMarket Perform—
15 May 2026WedbushInitiatesOutperform—
6 May 2026BTIGReiteratesBuy—
6 May 2026KeybancMaintainsOverweight—
6 May 2026StifelMaintainsBuy—
6 May 2026UBSMaintainsNeutral—
6 May 2026Wells FargoMaintainsEqual-Weight—
27 Apr 2026KeybancMaintainsOverweight—
17 Apr 2026Piper SandlerMaintainsOverweight—
24 Mar 2026Rothschild & CoInitiatesSell—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SOLV.

Market Radar

This page is one stock. Monday covers all of them.

SOLV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SOLV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Solventum Corp. returned +6.3% against +6.9% for the S&P 500, dividends included.

SOLV vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120Jan 26Apr 26Jul 26Oct 26SOLVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SOLV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+1.4%
Analysts raising
8
Analysts cutting
3
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
94.9×

Cheaper than 9% of US stocks

Price / sales
1.8×

Cheaper than 52% of US stocks

Price / book
3.0×

Cheaper than 31% of US stocks

EV / EBITDA
19.1×

Cheaper than 22% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
58.2%

Higher than 71% of US stocks

Operating margin
5.9%

Higher than 56% of US stocks

Net margin
—
Returns & dividend
Return on equity
3.2%

Higher than 49% of US stocks

Return on assets
2.1%

Higher than 59% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Solventum Corp. has a market value of $14.4B and an enterprise value of $19.2B.

  • Revenue in the twelve months to 30 June 2026: $8.3B. The latest quarter grew 2.2% year on year.

  • Net income over the same four quarters: $1.4B, a 17.3% net margin.

  • Diluted earnings per share, trailing twelve months: $8.18.

  • Free cash flow in the twelve months to 30 June 2026: −$118.0M.

  • Shares outstanding: 170.1M.

  • Trailing P/E: 94.9×; forward P/E: 11.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Solventum Corp. employs 20,584 people — $404K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

SOLV and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
SOLVSolventum Corp.$14.4B76
BAXBaxter International, Inc.$13.1B94
COOThe Cooper Cos., Inc.$11.5B71
ALGNAlign Technology, Inc.$11.1B83
RGENRepligen Corp.$10.4B87
AVTRAvantor, Inc.$10.1B83
ATRAptarGroup, Inc.$9.2B62

Take a look at SOLV’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Solventum Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SOLV

What is the SOLV stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Solventum Corp. have a median 12-month price target of $100, with estimates ranging from $75 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SOLV stock a buy right now?

Of the 15 analysts covering Solventum Corp., 8 rate it a Buy, 5 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Solventum Corp. 76 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SOLV?

As at 21 Nov 2026, Solventum Corp. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).

Will SOLV stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +18.3% from the last close, and Ticker Nerd's factor model ranks Solventum Corp. 76 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SOLV stock forecast for 2030?

No analyst covering Solventum Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SOLV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $75 to $115 over the next 12 months.

How has SOLV stock performed over the past year?

Solventum Corp. returned +6.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Solventum Corp. do?

Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, and medical electrodes.

Company

About Solventum Corp.

Solventum Corporation is a healthcare company that develops and commercializes a broad portfolio of products and software designed to address clinical and operational needs across care settings. Its Medsurg business provides wound care, skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, and medical electrodes. The Dental Solutions segment offers products used in restorative and orthodontic workflows, including brackets, aligners, cements, and bonding agents. Through Health Information Systems, Solventum supplies software and services that support physician documentation, coding automation, speech recognition, and data visualization for healthcare organizations. The company serves customers in the United States and internationally through direct sales, distribution, key account management, inside sales, and e-commerce. Headquartered in Eagan, Minnesota, Solventum focuses on technologies that support safer, more efficient healthcare delivery.

CEO Mr. Bryan C. Hanson · 20,584 employees · United States · https://www.solventum.com